The P-I/II clinical trial (AMPLIFY-7P) evaluates the safety & efficacy of ELI-002 7P in patients with KRAS/NRAS mutated solid tumors. The P-Ia and P-Ib portions of the study will show the RP2D & evaluate 3 dose expansion cohorts, respectively, while P-II will enroll additional patients to be assessed in a 2:1 randomized cohort of ELI-002 7P vs observation
The P-I/II clinical trial (AMPLIFY-7P) is designed based on the data obtained from the ongoing P-I clinical trial (AMPLIFY-201) evaluating a 2-peptide formulation of ELI-002
ELI-002 is an investigational cancer vaccine developed using Elicio’s proprietary lymph node targeting Amphiphile (AMP) technology. ELI-002 7P contains 7 KRAS & NRAS peptide-based antigens (G12D, G12R, G12V, G12A, G12C, G12S, G13D)
Ref: Elicio Therapeutics | Image: Elicio Therapeutics
Related News:- Elicio Therapeutics Entered into a Definitive Merger Agreement with Angion to Advance ELI-002 for Cancer
